Beijing Danatlas Pharmaceutical Technology prepares new PARG inhibitors
May 4, 2026
Beijing Danatlas Pharmaceutical Technology Co. Ltd. has patented new crystalline salt forms of poly(ADP-ribose) glycohydrolase (PARG) inhibitors reported to be useful for the treatment of cancer.